A Phase 2 interventional study of obinutuzumab (RO5072759) and rituximab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 71 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-19.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. obinutuzumab · Lymphoma, Non-Hodgkin.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, this one is the 5th largest by enrollment, is the only one that started in 2008, is one of 8 in phase 2, and was the 1st registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →3 of the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin are open now, in 1 country. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
New York Medical College · Sites in United States
Ages 3–31
Henan Cancer Hospital
Ages 18+
By country, each count listing its studies:
obinutuzumab: first FDA approval 2013 (GAZYVA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 12 · Phase 3 2
First in 2008; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 175 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 41 across the 15 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 15 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche: 1 open now, 6 under way, 1 of them phase 3. Of 47 finished, 22 (47%) have results posted.
Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 18th largest by enrollment of the 49 interventional ones that give a count, is one of 4 that started in 2008, is one of 8 in phase 2, and was the 9th registered.
Hoffmann-La Roche’s Lymphoma, Non-Hodgkin studies by the year they started, since 1997.
3 of the studies testing obinutuzumab in Lymphoma, Non-Hodgkin that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02393157New York Medical CollegeObinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL | 2026-12 |
| NCT04077723Hoffmann-La RocheA Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | 2026-12-28 |
| NCT03223610National Cancer Institute (NCI)Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma | 2027-08-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing obinutuzumab in Lymphoma, Non-Hodgkin, from their registry updates:
Among Hoffmann-La Roche’s 54 in Lymphoma, Non-Hodgkin:
This tab as a report to print or save as PDF → With an account.
This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 1000 mg obinutuzumab intravenous (IV) infusion once a week on Days 1, 8, 15, and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression, were eligible to receive a 1000 mg IV infusion every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
Drug: obinutuzumab (RO5072759)
Participants received 375 mg/m\^2 rituximab IV infusion once a week on Days 1, 8, 15 and 22 in the Induction Period. 2 months following the last infusion, participants without disease progression were eligible to receive a 375 mg/m\^2 rituximab IV infusion once every two months for 2 years in the Extension Period. All participants received oral acetaminophen/ paracetamol (1000 mg) and an antihistamine such as diphenhydramine (50-100 mg), 30-60 minutes prior to each infusion.
Drug: rituximab
1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
Also known as: RO5072759, GA101, GAZYVA®
375 mg/m\^2 rituximab IV infusion once a week for 4 weeks.
Percentage of Participants With Overall Response At the End of Induction Period
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigator at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
Time frame: Randomization to clinical cutoff: 01 September 2011 (Up to 70 days)
Percentage of Participants With Complete Response at the End of the Induction Period
Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR is defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. All lymph nodes and nodal masses must have regressed to normal size. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination. Any macroscopic nodules in any organs detectable on imaging techniques should no longer be present. Other organs considered to be enlarged before therapy due to involvement by lymphoma, such as liver and kidneys, must have decreased in size. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site.
Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Percentage of Participants With Partial Response (PR) at the End of the Induction Period
Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
Time frame: Randomization to clinical cutoff : 01 September 2011 (Up to 70 days)
Number of Participants With Improved Overall Response During the Extended Treatment Period
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Percentage of Participants With Best Overall Response Achieved at Any Time During the Study Treatment
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Progression-Free Survival (PFS)
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Percentage of Participants With Progression-Free Survival (PFS) Events
The percentage of participants with progression, relapse, or death events from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Event Free Survival
Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Percentage of Participants With Event Free Survival (EFS) Events
Percentage of participants with Event Free Events: disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Duration of Response
Duration of Response was defined as the date the response, either Complete Response (CR) or Partial Response (PR), was first recorded until the date of Disease Progression or death due to any cause. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease. Disease Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Obinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2)
Blood was collected for Pharmacokinetic (PK) Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Terminal Half-Life was calculated in days.
Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Serum PK Parameter: Maximum Serum Concentration (Cmax)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 1, 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was calculated in micrograms/milliliter (μg/mL).
Time frame: Day 1 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours post-infusion), Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUClast was calculated in days\* micrograms/milliliter (μg/mL)
Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLsst was calculated in milliliter/day (mL/day)
Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss was calculated in liters (L).
Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUCtau was calculated in days\* micrograms/milliliter (μg/mL)
Time frame: Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Obinutuzumab Trough Serum Concentration (Ctrough)
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Ctrough was calculated in micrograms/milliliter (μg/mL).
Time frame: Days 8 and 15 (pre-infusion, at end of infusion), Day 22 (pre-infusion, at end of infusion, 3-6, 20-28, 66-80 hours, 6-8, 12-16, 18-24, 28-56 days post-infusion)
Number of Participants With Peripheral Blood B-Cell Depletion
Blood was collected and sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry at the end of the induction period. B-cell depletion was defined as a CD19 result 5 % of the Baseline value after at least one dose of study drug was administered.
Time frame: Day 22
Number of Participants With Peripheral Blood B-Cell Recovery
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as the time point when the CD-19 values return to ≥ 50% of baseline levels. The number of participants with B-cell recovery from End of Induction (treatment) Phase to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) or Recovery without PD. PD required one of the following: 50 % increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50 % increase in the longest diameter of any previous site of lymphadenopathy, 50 % increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.
Time frame: End of last dose + 6 Months Follow-Up
Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory result), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months) [Includes all AEs reported 28 days after last dose and all Related SAEs regardless of time of last dose.]
Number of Participants With Infusion Related Reactions
Infusion Related Reactions were AEs that occurred during the infusion or within 24 hours of the infusion.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
Number of Participants With Human Anti-Chimeric Antibodies (HACA)
Blood was collected on Day 1 and was sent to a central laboratory for analysis of human anti-chimeric antibodies (anti-rituximab antibodies) using a validated enzyme-linked immunosorbent assay (ELISA). HACA samples were not collected for participants randomized to the rituximab arm.
Time frame: Day 1
Number of Participants With Human Anti-Human Antibodies (HAHA)
Blood was collected on Day 1 pre-infusion, during the safety follow-up for those patients who did not enter the Extension period and 6 months after the last infusion of the Extension Period if applicable. Blood was sent to a central laboratory and was tested for anti-obinutuzumab antibodies using a validated enzyme-linked immunosorbent assay (ELISA). HAHA samples were not collected for participants randomized to the rituximab arm.
Time frame: Randomization to Clinical cutoff: 07 March 2013 (Up to 43.2 months)
| Milestone | Rituximab | Obinutuzumab |
|---|---|---|
| Started | 87 | 88 |
| Received treatment | 86 | 87 |
| Completed | 79 | 83 |
| Not completed | 8 | 5 |
| Withdrew: Adverse event or intercurrent illness | 3 | 3 |
| Withdrew: Insufficient therapeutic response | 2 | 0 |
| Withdrew: Violation of selection criteria at entry | 1 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Refused treatment/ did not cooperate | 0 | 1 |
| Withdrew: Withdrew consent | 1 | 0 |
| Milestone | Rituximab | Obinutuzumab |
|---|---|---|
| Started | 72 | 73 |
| Completed | 30 | 30 |
| Not completed | 42 | 43 |
| Withdrew: Adverse event or intercurrent illness | 6 | 7 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Refused treatment/did not cooperate | 2 | 1 |
| Withdrew: Insufficient therapeutic response | 30 | 33 |
| Withdrew: Administrative/other | 3 | 1 |
| Milestone | Rituximab | Obinutuzumab |
|---|---|---|
| Started | 55 | 51 |
| Completed | 28 | 34 |
| Not completed | 27 | 17 |
| Withdrew: Administrative/other | 6 | 8 |
| Withdrew: Death | 3 | 3 |
| Withdrew: Insufficient therapeutic response | 16 | 5 |
| Withdrew: Withdrew consent | 2 | 1 |
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigator at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Percentage of Participants With Overall Response At the End of Induction Period | 33.3 | 44.6 |
Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR is defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. All lymph nodes and nodal masses must have regressed to normal size. The spleen, if considered to be enlarged before therapy on the basis of a CT scan, must have regressed in size and must not be palpable on physical examination. Any macroscopic nodules in any organs detectable on imaging techniques should no longer be present. Other organs considered to be enlarged before therapy due to involvement by lymphoma, such as liver and kidneys, must have decreased in size. If the bone marrow was involved by lymphoma before treatment, the infiltrate must be cleared on repeat bone marrow aspirate and biopsy of the same site.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Percentage of Participants With Complete Response at the End of the Induction Period | 5.3 (1.5 to 13.1) | 12.2 (5.7 to 21.8) |
Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Percentage of Participants With Partial Response (PR) at the End of the Induction Period | 28.0 (18.2 to 39.6) | 32.4 (22.0 to 44.3) |
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Complete Response | 18.7 (10.6 to 29.3) | 35.1 (24.4 to 47.1) |
| Partial Response | 45.3 (33.8 to 57.3) | 31.1 (20.8 to 42.9) |
| Stable Disease | 26.7 (17.1 to 38.1) | 21.6 (12.9 to 32.7) |
| Progressive Disease | 5.3 (1.5 to 13.1) | 8.1 (3.0 to 16.8) |
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators at end of induction treatment. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson.
| Participants | Rituximab | Obinutuzumab |
|---|---|---|
| Number of Participants With Improved Overall Response During the Extended Treatment Period | 31 | 32 |
Overall response was defined as Complete Response (CR), Complete Response/Unconfirmed (CRu) or Partial Response (PR) as assessed by investigators during study treatment (induction or extended treatment phase). Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. CRu was CR plus one or more of the following: A residual lymph node mass greater than 1.5 cm in greatest transverse diameter that has regressed by more than 75% in the sum of the products of the greatest diameter (tumors)(SPD) and/or indeterminate bone marrow. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Complete Response | 22.7 (13.8 to 33.8) | 41.9 (30.5 to 53.9) |
| Partial Response | 41.3 (30.1 to 53.3) | 24.3 (15.1 to 35.7) |
| Stable Disease | 26.7 (17.1 to 38.1) | 21.6 (12.9 to 32.7) |
| Progressive Disease | 5.3 (1.5 to 13.1) | 8.1 (3.0 to 16.8) |
| No Response Assessment | 4.0 (NA to NA) | 4.1 (NA to NA) |
PFS was defined as the time from randomization to the first occurrence of progression, relapse, or death from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
| Days | Rituximab | Obinutuzumab |
|---|---|---|
| Progression-Free Survival (PFS) | 772 (425 to 867) | 536 (394 to NA) |
The percentage of participants with progression, relapse, or death events from any cause as assessed by the Investigator. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Percentage of Participants With Progression-Free Survival (PFS) Events | 57.7 | 51.4 |
Event-free survival (EFS) was defined as the time between date of randomization and the date of disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
| Days | Rituximab | Obinutuzumab |
|---|---|---|
| Event Free Survival | 472.0 (362 to 772) | 472.0 (318 to 605) |
Percentage of participants with Event Free Events: disease progression/relapse, death, or start of a new anti-leukemic therapy. Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy. Relapse was defined as the appearance of any new lesion or increase by ≥ 50% in the size of previously involved sites and/or a ≥ 50% increase in greatest diameter of any previously identified node greater than 1 cm in its short axis or in the SPD of more than one node.
| Percentage of participants | Rituximab | Obinutuzumab |
|---|---|---|
| Percentage of Participants With Event Free Survival (EFS) Events | 64.0 | 63.5 |
Duration of Response was defined as the date the response, either Complete Response (CR) or Partial Response (PR), was first recorded until the date of Disease Progression or death due to any cause. Computed tomography imaging was used for the primary assessment of tumor response per 1999 criteria by Cheson. CR was defined as the disappearance of all clinical and radiographic evidence of disease, disease-related symptoms and normalization of biochemical abnormalities of NHL. PR was defined as 50% decrease in SPD of the 6 largest dominant nodes or nodal masses. No increase in the size of the other nodes, liver, or spleen. Splenic and hepatic nodules must regress by at least 50% in the SPD. No new sites of disease. Disease Progression was defined as a ≥ 50% increase from nadir in the SPD of any previously identified abnormal node and/or the appearance of any new lesion during or at the end of therapy.
| Months | Rituximab | Obinutuzumab |
|---|---|---|
| Duration of Response | 809 (412 to NA) | NA (672 to NA) |
Blood was collected for Pharmacokinetic (PK) Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Terminal Half-Life was calculated in days.
| days | Obinutuzumab |
|---|---|
| Obinutuzumab Serum PK Parameter: Terminal Half-Life (t1/2) | 41.0 ± 28.6 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 1, 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Cmax was calculated in micrograms/milliliter (μg/mL).
| μg/mL | Obinutuzumab |
|---|---|
| Cycle 1 (n=74) | 292 ± 87.4 |
| Cycle 2 (n=78) | 448 ± 129 |
| Cycle 3 (n=77) | 561 ± 158 |
| Cycle 4 (n=77) | 692 ± 213 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUClast was calculated in days\* micrograms/milliliter (μg/mL)
| day*μg/mL | Obinutuzumab |
|---|---|
| Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve (AUClast) | 23400 ± 10300 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). CLsst was calculated in milliliter/day (mL/day)
| mL/day | Obinutuzumab |
|---|---|
| Obinutuzumab Serum PK Parameter: Clearance at Steady-State (CLss) | 308 ± 470 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Vss was calculated in liters (L).
| Liter | Obinutuzumab |
|---|---|
| Obinutuzumab Serum PK Parameter: Volume of Distribution at Steady-State (Vss) | 14.6 ± 9.8 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycle 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). AUCtau was calculated in days\* micrograms/milliliter (μg/mL)
| day*μg/mL | Obinutuzumab |
|---|---|
| Obinutuzumab Serum PK Parameter: Area Under the Concentration Curve Between Dosing Interval (AUCtau) | 4370 ± 1340 |
Blood was collected for PK Parameters before and after dose administration of obinutuzumab in Induction Phase Cycles 2, 3 and 4. Serum samples were sent to a central lab and were analyzed for obinutuzumab using a validated enzyme-linked immunosorbent assay (ELISA). Ctrough was calculated in micrograms/milliliter (μg/mL).
| μg/mL | Obinutuzumab |
|---|---|
| Cycle 2 (n=78) | 154 ± 62.7 |
| Cycle 3 (n=77) | 301 ± 119 |
| Cycle 4 (n=75) | 418 ± 147 |
Blood was collected and sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry at the end of the induction period. B-cell depletion was defined as a CD19 result 5 % of the Baseline value after at least one dose of study drug was administered.
| Participants | Rituximab | Obinutuzumab |
|---|---|---|
| Number of Participants With Peripheral Blood B-Cell Depletion | 80 | 82 |
Blood was sent to a central laboratory for the evaluation of cluster of differentiation 19 (CD19) by flow cytometry. B-cell recovery was defined as the time point when the CD-19 values return to ≥ 50% of baseline levels. The number of participants with B-cell recovery from End of Induction (treatment) Phase to 6 months of Follow-up is reported in two categories: Recovery with Progressive Disease (PD) or Recovery without PD. PD required one of the following: 50 % increase in the absolute number of circulating lymphocytes, Appearance of new palpable lymph nodes, 50 % increase in the longest diameter of any previous site of lymphadenopathy, 50 % increase in the enlargement of the liver and/or spleen or Transformation to a more aggressive histology.
| Participants | Rituximab | Obinutuzumab |
|---|---|---|
| Recovery with PD | 0 | 2 |
| Recovery without PD | 1 | 0 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory result), symptom, or disease temporally associated with the use of an investigational medicinal product (IMP) or other protocol-imposed intervention, regardless of attribution. A SAE was any AE that was one of the following: fatal, life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to the investigational product or considered a significant medical event by the investigator. Additional information about AEs can be found in the Adverse Event Section.
| Participants | Rituximab | Obinutuzumab |
|---|---|---|
| AE | 74 | 83 |
| SAE | 17 | 21 |
Infusion Related Reactions were AEs that occurred during the infusion or within 24 hours of the infusion.
| Participants | Rituximab | Obinutuzumab |
|---|---|---|
| Number of Participants With Infusion Related Reactions | 44 | 70 |
Blood was collected on Day 1 and was sent to a central laboratory for analysis of human anti-chimeric antibodies (anti-rituximab antibodies) using a validated enzyme-linked immunosorbent assay (ELISA). HACA samples were not collected for participants randomized to the rituximab arm.
| Participants | Obinutuzumab |
|---|---|
| Number of Participants With Human Anti-Chimeric Antibodies (HACA) | 1 |
Blood was collected on Day 1 pre-infusion, during the safety follow-up for those patients who did not enter the Extension period and 6 months after the last infusion of the Extension Period if applicable. Blood was sent to a central laboratory and was tested for anti-obinutuzumab antibodies using a validated enzyme-linked immunosorbent assay (ELISA). HAHA samples were not collected for participants randomized to the rituximab arm.
| Participants | Obinutuzumab |
|---|---|
| Number of Participants With Human Anti-Human Antibodies (HAHA) | 0 |
Collected over First dose of study drug to 28 days past last dose of study drug (Up to 27 Months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab | — | 13/86 (15.1%) | 70/86 (81.4%) |
| Obinutuzumab | — | 13/87 (14.9%) | 79/87 (90.8%) |
| Event | Rituximab | Obinutuzumab |
|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 2/86 | 2/87 |
| PneumoniaInfections and infestations | 2/86 | 2/87 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/86 | 2/87 |
| NeutropeniaBlood and lymphatic system disorders | 1/86 | 0/87 |
| CellulitisInfections and infestations | 1/86 | 0/87 |
| Fibula fractureInjury, poisoning and procedural complications | 1/86 | 0/87 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/86 | 0/87 |
| Cardio-respiratory arrestCardiac disorders | 1/86 | 0/87 |
| Hepatitis cholestaticHepatobiliary disorders | 1/86 | 0/87 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/86 | 0/87 |
| Event | Rituximab | Obinutuzumab |
|---|---|---|
| Infusion related reactionsInjury, poisoning and procedural complications | 43/86 | 62/87 |
| FatigueGeneral disorders | 17/86 | 23/87 |
| CoughRespiratory, thoracic and mediastinal disorders | 8/86 | 20/87 |
| PyrexiaGeneral disorders | 9/86 | 5/87 |
| Upper respiratory tract infectionInfections and infestations | 9/86 | 9/87 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/86 | 4/87 |
| NauseaGastrointestinal disorders | 7/86 | 8/87 |
| Decreased appetiteMetabolism and nutrition disorders | 3/86 | 8/87 |
| HeadacheNervous system disorders | 7/86 | 8/87 |
| DiarrhoeaGastrointestinal disorders | 7/86 | 7/87 |
| Age, Customized(participants) | Rituximab | Obinutuzumab | Total |
|---|---|---|---|
| <65 years | 49 | 47 | 96 |
| 65-70 years | 22 | 22 | 44 |
| >70 years | 16 | 19 | 35 |
| Sex: Female, Male(Participants) | Rituximab | Obinutuzumab | Total |
|---|---|---|---|
| Female | 43 | 42 | 85 |
| Male | 44 | 46 | 90 |
The record gives a start of Jan 2008, a primary completion of Sep 2011 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 2 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Obinutuzumab